Micropump-based Licensing Opportunities

Micropump®-based Licensing Opportunities

 

  Genvir™ Metformin XL Omeprazole XL Co-amoxyclav XR
Key characteristics Controlled release acyclovir Controlled release metformin Controlled release omeprazole Combination of controlled release amoxicillin and immediate release clavulanate
Competitive Advantages
  • Increase the bioabsorption time of acyclovir
  • Reduction of the daily dosage (twice-a-day dosage vs 5 times a day for acyclovir IR)
  • Cost effective herpes treatment solution
  • Reduction of inter-subject variability
  • Potential combination with other anti-diabetic/ cardiovascular drugs
  • Available as sachet & orodispersible tablets
  • Significantly higher mean gastric pH over 24 hours compared to marketed Nexium®
  • Potential liquid formulation easier to swallow for pediatrics or geriatrics
  • Improved duration of action and reduction of dosage compared to marketed Augmentin®
  • Available as suspension/sachet
Clinical Stage Phase 3 Phase 1 Phase 1 Phase 1
Indication Acute Genital Herpes Type 2 Diabetes Gastroesophageal Reflux Disease Infection
Indication Global Market* $3.2B
($6B by 2016)		 $24B
($36.1B by 2017)		 $19.6B $41B

(* Market data for 2010 from various sources)

Micropump-based Products are designed to improve patient compliance

  • Easy adjustment to different dosage forms: pills, tablets, sachet, liquid suspension (LiquiTime™);
  • Easy combination of drugs whose release can be controlled separately;
  • Taste-masking; and,

  • Cost effective.

Example of the extended bioavailability of Metformin XL